Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Phase 3 outcomes (2026): TRIUMPH-1 (May 2026, n=2,339) demonstrated 28.3% mean weight loss at 12mg weekly the largest published Phase 3 result of any GLP-1 class compound to date, exceeding tirzepatide (22.5% in SURMOUNT-1) and semaglutide (14.9% in STEP-1) at comparable timepoints
Systemic : Fatigue, dizziness, or flares triggered by stress, heat, or specific foods
Here is how the two peptides match up across the goals we see most often
In the Retatrutide diabetes trial, gastrointestinal adverse events appeared in roughly 35 percent of treated participants, the same family of effects seen across this drug class, and no severe low-blood-sugar episodes or deaths were reported
US$ 20.25
US$ 20.39
US$ 29.18
US$ 26.36
US$ 25.39
US$ 27.98
